Ocunova

Focused on Ophthalmology

What We Do

Commitment to Innovation

Ocunova is developing a novel treatment for Dry Eye Syndrome. Unlike most lubricants, rewetting solutions and anti inflammatories, our therapy targets the specific type of Dry Eye the afflicts people with diabetes. Our novel eye drop solution is the subject of extensive research and is patent protected.

Clinical Development

Our novel compound (OCU-001) has been studied in multiple animal models and demonstrated safe in a phase 1 study. We are preparing to assess the safety and efficacy of OCU-001 in a human clinical study in the near future.

Compelling Data

Researchers from Penn State University have demonstrated in diabetic dry eye animal models that OCU-001 can quickly restore normal tear secretions and maintain normal tearing for up to 48 hours. Our scientists believe the unique mechanism of OCU-001 may help the millions of diabetics suffering with Dry Eye Syndrome 

Contact Us

Send Message

Ocunova Management Team

Michael Shine - CEO


Joseph Messina - COO


Greg Hockel - Regulatory


Gary Smith - Legal